Colchicine in Cardiac Surgery: The COCS Randomized Clinical Trial
Background. In patients who underwent cardiac surgery, first-time postoperative atrial fibrillation (POAF) is associated with increased incidence of hospital-acquired complications and mortality. Systemic inflammation is one of confirmed triggers of its development. The anti-inflammatory properties of colchicine can be effective for the POAF prevention. However, the results of several studies were questionable and required further investigation. Hence, we aimed to evaluate the effectiveness of low-dose short-term colchicine administration for POAF prevention in patients after the open-heart surgery. This double-blind randomized placebo-controlled trial included 267 patients, but 27 of them dropped out in the course of the study. Study subjects received the test drug on the day before the surgery and on postoperative days 2, 3, 4 and 5. The rhythm control was conducted immediately after the operation and until the discharge from the hospital. The final analysis included 240 study subjects: 113 in the colchicine group and 127 in the placebo group. POAF was observed in 21 (18.6%) patients of the colchicine group vs. 39 (30.7%) control patients (OR 0.515; 95% Cl 0.281–0.943; p = 0.029). We observed no statistically significant differences between the patient groups in the secondary endpoints of the study (hospital mortality, respiratory failure, stroke, bleeding, etc.). For other parameters characterizing the severity of inflammation (pericardial effusion, pleural effusion, WBC count, neutrophil count), there were statistically significant differences between the groups in the early postoperative period (days 3 and 5). Also, statistically significant differences between the groups in the frequency of adverse events were revealed: the incidence of diarrhea in the colchicine group was 25.7% vs. 11.8% in the placebo group (OR 2.578; 95% Cl 1.300–5.111; p = 0.005); for abdominal pain, incidence values were 7% vs. 1.6%, correspondingly (OR 4.762; 95% Cl 1.010–22.91; p = 0.028). Thus, there were statistically significant differences between groups in the primary endpoint, thereby confirming the effectiveness of short-term colchicine use for the POAF prevention after coronary artery bypass grafting and/or aortic valve replacement. Also, we detected statistically significant differences between groups in the frequency of side effects to colchicine: diarrhea and abdominal pain were more common in the colchicine group. This clinical trial is registered with ClinicalTrials database under a unique identifier: NCT04224545.
Top-30
Journals
1
2
|
|
European Journal of Internal Medicine
2 publications, 9.52%
|
|
Journal of Cardiovascular Development and Disease
1 publication, 4.76%
|
|
Frontiers in Cardiovascular Medicine
1 publication, 4.76%
|
|
Europace
1 publication, 4.76%
|
|
Canadian Journal of Cardiology
1 publication, 4.76%
|
|
Cureus
1 publication, 4.76%
|
|
Frontiers in Physiology
1 publication, 4.76%
|
|
Clinical Medicine (Russian Journal)
1 publication, 4.76%
|
|
International Journal of Cardiology
1 publication, 4.76%
|
|
Journal of Cardiovascular Pharmacology
1 publication, 4.76%
|
|
British Journal of Pharmacology
1 publication, 4.76%
|
|
Journal of Cardiovascular Medicine
1 publication, 4.76%
|
|
IJC Heart and Vasculature
1 publication, 4.76%
|
|
Australian Critical Care
1 publication, 4.76%
|
|
BMJ Open
1 publication, 4.76%
|
|
Heart Rhythm O2
1 publication, 4.76%
|
|
Scandinavian Cardiovascular Journal
1 publication, 4.76%
|
|
Rational Pharmacotherapy in Cardiology
1 publication, 4.76%
|
|
Russian Journal of Cardiology
1 publication, 4.76%
|
|
Nauchno-Prakticheskaya Revmatologiya
1 publication, 4.76%
|
|
1
2
|
Publishers
1
2
3
4
5
6
7
|
|
Elsevier
7 publications, 33.33%
|
|
Frontiers Media S.A.
2 publications, 9.52%
|
|
Ovid Technologies (Wolters Kluwer Health)
2 publications, 9.52%
|
|
Silicea - Poligraf, LLC
2 publications, 9.52%
|
|
MDPI
1 publication, 4.76%
|
|
Oxford University Press
1 publication, 4.76%
|
|
Springer Nature
1 publication, 4.76%
|
|
Medical Informational Agency Publishers
1 publication, 4.76%
|
|
Wiley
1 publication, 4.76%
|
|
BMJ
1 publication, 4.76%
|
|
Taylor & Francis
1 publication, 4.76%
|
|
Mediar Press
1 publication, 4.76%
|
|
1
2
3
4
5
6
7
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.